Clinical utility of C-reactive protein to predict treatment response during cystic fibrosis pulmonary exacerbations

about

C-reactive protein/albumin ratio is associated with lung function among children/adolescents with cystic fibrosis: a three-year longitudinal study.Recent advances in the understanding and management of cystic fibrosis pulmonary exacerbations.

P2860

Q47265056-F031DB4B-F329-4B4A-9EDD-CF8A709F9CE5 Q55437809-4941BB52-2869-4234-A4DC-0DE20644D6D9

P2860

Clinical utility of C-reactive protein to predict treatment response during cystic fibrosis pulmonary exacerbations

Item

http://www.wikidata.org/entity/Q36274154

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Clinical utility of C-reactive ...... brosis pulmonary exacerbations

@ast

Clinical utility of C-reactive ...... brosis pulmonary exacerbations

@en

type

Item

label

Clinical utility of C-reactive ...... brosis pulmonary exacerbations

@ast

Clinical utility of C-reactive ...... brosis pulmonary exacerbations

@en

prefLabel

Clinical utility of C-reactive ...... brosis pulmonary exacerbations

@ast

Clinical utility of C-reactive ...... brosis pulmonary exacerbations

@en

P1476

Clinical utility of C-reactive ...... brosis pulmonary exacerbations

@en

P2093

Ashutosh Sharma

http://www.w3.org/2001/XMLSchema#string

Bradley S Quon

http://www.w3.org/2001/XMLSchema#string

Gordon Kirkpatrick

http://www.w3.org/2001/XMLSchema#string

Kate Skolnik

http://www.w3.org/2001/XMLSchema#string

Pearce Wilcox

http://www.w3.org/2001/XMLSchema#string

Virginia Chen

http://www.w3.org/2001/XMLSchema#string

Zsuzsanna Hollander

http://www.w3.org/2001/XMLSchema#string

P2860

Toxicity of polymyxins: a systematic review of the evidence from old and recent studies

Standardisation of spirometry

Predictive 5-year survivorship model of cystic fibrosis.

Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation

The cell wall components peptidoglycan and lipoteichoic acid from Staphylococcus aureus act in synergy to cause shock and multiple organ failure

Quality of life in children and adolescents with cystic fibrosis: implications for optimizing treatments and clinical trial design.

Candidate markers associated with the probability of future pulmonary exacerbations in cystic fibrosis patients.

Effect of treatment of cystic fibrosis pulmonary exacerbations on systemic inflammation.

Plasma tumour necrosis factor alpha in cystic fibrosis

Effect of antibiotic treatment on inflammatory markers and lung function in cystic fibrosis patients with Pseudomonas cepacia.

P304

e0171229

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0171229

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-02-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28178305

http://www.w3.org/2001/XMLSchema#string

P921

cystic fibrosis

P932

5298271

http://www.w3.org/2001/XMLSchema#string

Clinical utility of C-reactive protein to predict treatment response during cystic fibrosis pulmonary exacerbations

about

P2860

P2860

Clinical utility of C-reactive protein to predict treatment response during cystic fibrosis pulmonary exacerbations

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P932